Illustration of biochemical basements of the treatment of brest cancer with the monoclonal antibody Herceptin (Trastuzumab). The antibody Herceptine is target to the antigen her2/neu. By Herceptine marked her2/neu antigenes detects carcinoma cells that can be killed by the immune system.
